[Federal Register: July 24, 2008 (Volume 73, Number 143)]
[Notices]               
[Page 43243]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr24jy08-76]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

 
Prospective Grant of Exclusive License: Respiratory Syncytial 
Virus Vaccine or Therapeutic

AGENCY: Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention 
(CDC), Technology Transfer Office, Department of Health and Human 
Services (DHHS), is contemplating the grant of a worldwide exclusive 
license to practice the inventions embodied in the patent referred to 
below to Trellis Bioscience, Inc., having a place of business in South 
San Francisco, CA. The patent rights in these inventions have been 
assigned to the government of the United States of America. The 
patent(s) to be licensed are: U.S. Patent Application 11/139,372 
entitled ``Compositions and Methods for Modulating RSV Infection and 
Immunity,'' priority date 10.18.2000, and all related foreign patent 
applications. CDC Technology ID No. I-022-00.
    Status: Published.
    Priority Date: 10.18.2000
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
    Technology: This technology provides new methods for prevention and 
treatment of respiratory syncytial virus (RSV) infection.

ADDRESSES: Requests for a copy of this patent application, inquiries, 
comments, and other materials relating to the contemplated license 
should be directed to Andrew Watkins, J.D., Ph.D., Director, Technology 
Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 
Buford Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-
8600; facsimile: (770) 488-8615. Applications for a license filed in 
response to this notice will be treated as objections to the grant of 
the contemplated license. Only written comments and/or applications for 
a license which are received by CDC within thirty days of this notice 
will be considered. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: June 17, 2008.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
 [FR Doc. E8-16943 Filed 7-23-08; 8:45 am]

BILLING CODE 4163-18-P